Liraglutide vs Adipotide
Comprehensive side-by-side comparison of mechanisms, dosing, side effects, and research
Also: Victoza, Saxenda
Liraglutide is a once-daily injectable GLP-1 receptor agonist, a synthetic peptide that shares about 97% of its sequence with the natural gut hormone GLP-1 but is engineered with a fatty acid chain so it survives in the body far longer. It is FDA-approved as Victoza for type 2 diabetes (2010) and as Saxenda for chronic weight management (2014), and is one of the most studied drugs in its class. As of 2024 a generic version is also FDA-approved.
Also: FTPP, Fat-Targeted Proapoptotic Peptide
Adipotide is an experimental peptide built to kill fat tissue by cutting off its blood supply. One half homes in on prohibitin, a protein on the blood vessels that feed white fat, and the other half is a cell-killing sequence that triggers those vessel cells to self-destruct. It produced striking weight loss in obese mice and monkeys, but it also caused kidney damage in every primate species tested, and its only human trial was terminated after enrolling 4 people with no results ever posted.
Key Comparison Insights
- Liraglutide is FDA approved, while Adipotide remains in research stages.
- Both peptides belong to the Weight Loss category, suggesting similar primary applications.
- Liraglutide has stronger research evidence (FDA Approved) compared to Adipotide (Animal Studies).
Detailed Comparison
| Attribute | Liraglutide | Adipotide |
|---|---|---|
| Category | Weight Loss | Weight Loss |
| FDA Status | FDA Approved | Not FDA Approved |
| Clinical Status | Pre I II III IV FDA | Pre I II III IV FDA |
| Mechanism of Action | Liraglutide binds the GLP-1 receptor, the same target as the body's own incretin hormone. The clever part is glucose-dependence: it tells the pancreas to release insulin only when blood sugar is high, and it dials down glucagon (the hormone that raises blood sugar), so it lowers glucose without the crashing lows that older diabetes drugs can cause. It also slows how fast the stomach empties, which blunts post-meal sugar spikes and keeps you full longer. In the brain, it acts on GLP-1 receptors in the hypothalamus to turn down hunger signals and turn up satiety, which is the main driver of the weight loss seen with Saxenda. | The molecule has two parts joined together. The targeting part, CKGGRAKDC, was found by screening peptides in living mice for ones that stick to fat-tissue blood vessels; it binds prohibitin on the endothelial cells lining white fat vasculature. The payload, D(KLAKLAK)2, is a known pro-apoptotic peptide that disrupts mitochondrial membranes once inside a cell, setting off programmed cell death. Kill the vessels and the fat tissue they supply is starved and resorbed. This is a destructive mechanism, not a metabolic nudge like GLP-1 drugs, and that matters for safety: prohibitin is not exclusive to fat vessels, and the kidney's proximal tubule cells turned out to be a clear off-target casualty in monkeys. |
| Common Dosing | 1.8-3 mg daily Once daily | No established human dose Once daily in animal studies |
| Administration | Subcutaneous injection daily | Subcutaneous injection |
| Typical Duration | Long-term / chronic use | 28 days in the main monkey efficacy study; up to 63 days in dose-escalation |
| Best Time to Take | Morning or evening, consistent daily | No evidence-based timing |
Possible Side Effects May vary by individual |
|
|
| Research Summary | This is not a gray-area research peptide. Liraglutide has been through large, gold-standard human trials. The LEADER trial randomized 9,340 high-risk type 2 diabetes patients and found liraglutide cut the rate of cardiovascular death, heart attack, or stroke versus placebo (13.0% vs 14.9%, published in the New England Journal of Medicine in 2016). For weight, the SCALE program showed adults without diabetes lost roughly 8% of body weight at 56 weeks on the 3.0 mg Saxenda dose, far more than placebo. The most common side effects are gastrointestinal: nausea, vomiting, diarrhea, especially during dose escalation. Its labeling carries a boxed warning about thyroid C-cell tumors based on rodent studies, though a clear human link has not been established. In short, the evidence here is strong and human, not preliminary. | The concept came from Kolonin and colleagues (Nature Medicine, 2004), who reported that ablating fat vasculature reversed obesity in mice. The key primate study is Barnhart et al. (Science Translational Medicine, 2011) from MD Anderson. Obese rhesus monkeys given 0.43 mg/kg/day subcutaneously for 28 days lost 7.4% to 14.7% of body weight (average 10.6%) while controls stayed roughly flat, with MRI and DEXA confirming fat loss and clear improvements in insulin resistance. Lean monkeys at the same dose did not lose weight. The cost: serum creatinine rose in a dose-dependent way above 0.25 mg/kg, and the authors documented kidney tubule injury with glucose and protein in the urine, dehydration at higher doses, and low phosphorus and potassium. Most of it reversed within 28 days, but one treated monkey in each study still had residual changes. A first-in-human phase I trial at MD Anderson in obese men with metastatic prostate cancer (NCT01262664) started in 2012, enrolled only 4 patients, and was terminated at the investigator's request in 2019 with no results posted. That is the whole human record. Nobody knows the safe human dose, and the kidney signal is the opposite of reassuring. |
Frequently Asked Questions: Liraglutide vs Adipotide
What is the difference between Liraglutide and Adipotide?
Liraglutide is a weight loss peptide that liraglutide is a once-daily injectable glp-1 receptor agonist, a synthetic peptide that shares about 97% of its sequence with the natural gut hormone glp-1 but is engineered with a fatty acid chain so it survives in the body far longer. it is fda-approved as victoza for type 2 diabetes (2010) and as saxenda for chronic weight management (2014), and is one of the most studied drugs in its class. as of 2024 a generic version is also fda-approved. Adipotide is a weight loss peptide that adipotide is an experimental peptide built to kill fat tissue by cutting off its blood supply. one half homes in on prohibitin, a protein on the blood vessels that feed white fat, and the other half is a cell-killing sequence that triggers those vessel cells to self-destruct. it produced striking weight loss in obese mice and monkeys, but it also caused kidney damage in every primate species tested, and its only human trial was terminated after enrolling 4 people with no results ever posted. The main differences lie in their mechanisms of action and clinical applications.
Which is better, Liraglutide or Adipotide?
Neither is universally "better" - the choice depends on your specific goals. Liraglutide is typically used for weight loss purposes, while Adipotide is used for weight loss. Always consult with a healthcare provider to determine which may be appropriate for your situation.
Can Liraglutide and Adipotide be used together?
Some peptide protocols combine multiple compounds for synergistic effects. However, using Liraglutide and Adipotide together should only be considered under medical supervision, as both compounds have their own side effect profiles and potential interactions. Research on their combined use may be limited.